Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid.
|
7521344 |
1993 |
Benign Prostatic Hyperplasia
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Northern blot analysis of mRNA from normal and BPH stromal cells demonstrated a 5-fold decrease in IGFBP-2 mRNA (P < 0.001) and a 4-fold increase in IGFBP-5 mRNA (P < 0.01) in BPH compared to normal cells.
|
7525636 |
1994 |
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data demonstrate that estradiol down-regulates and ICI up-regulates an autocrine IGFBP-5 growth inhibitory pathway in MCF-7 cells and suggest that IGFBP-5 plays a role in modulation of proliferation of breast cancers by estrogens and antiestrogens.
|
8930399 |
1996 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We observed that the potent antiestrogen ICI 182780 (ICI) increased IGFBP-5 mRNA by 2-3-fold in 9,10-dimethyl-1,2-benzanthracene-induced mammary tumors in vivo.
|
8930399 |
1996 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In tumors that recurred several months following castration, IGFBP-5 mRNA and protein increased to levels that approached those in androgen-stimulated CWR22 tumors from noncastrate mice.
|
10218991 |
1999 |
Malignant neoplasm of prostate
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.
|
10218991 |
1999 |
Prostate carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Androgen receptor up-regulates insulin-like growth factor binding protein-5 (IGFBP-5) expression in a human prostate cancer xenograft.
|
10218991 |
1999 |
Benign Prostatic Hyperplasia
|
0.020 |
Biomarker
|
disease |
BEFREE |
IGFBP-5 immunohistochemical staining of prostate tissue specimens from patients was stronger in androgen-dependent and androgen-independent CaP than in areas of intraepithelial neoplasia (PIN) or benign prostatic hyperplasia (BPH).
|
10218991 |
1999 |
Prostatic Intraepithelial Neoplasias
|
0.010 |
Biomarker
|
disease |
BEFREE |
IGFBP-5 immunohistochemical staining of prostate tissue specimens from patients was stronger in androgen-dependent and androgen-independent CaP than in areas of intraepithelial neoplasia (PIN) or benign prostatic hyperplasia (BPH).
|
10218991 |
1999 |
Intraepithelial Neoplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
IGFBP-5 immunohistochemical staining of prostate tissue specimens from patients was stronger in androgen-dependent and androgen-independent CaP than in areas of intraepithelial neoplasia (PIN) or benign prostatic hyperplasia (BPH).
|
10218991 |
1999 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, tumor growth and serum prostate-specific antigen levels increased several fold faster in mice bearing IGFBP-5-transfected LNCaP tumors after castration, despite having similar tumor incidence and tumor growth rates with controls when grown in intact mice before castration.
|
10830316 |
2000 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Systemic administration of antisense IGFBP-5 ODN in mice bearing Shionogi tumors after castration significantly delayed time to progression to androgen independence and inhibited growth of AI recurrent tumors.
|
10850457 |
2000 |
Malignant neoplasm of prostate
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings suggest that up-regulation of IGFBP-5 after castration serves to enhance IGF bioactivity and raise the possibility that the response of prostate cancer to androgen withdrawal can be enhanced by strategies, such as antisense IGFBP-5 ODN therapy, that target IGF signal transduction.
|
10850457 |
2000 |
Prostate carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
These findings suggest that up-regulation of IGFBP-5 after castration serves to enhance IGF bioactivity and raise the possibility that the response of prostate cancer to androgen withdrawal can be enhanced by strategies, such as antisense IGFBP-5 ODN therapy, that target IGF signal transduction.
|
10850457 |
2000 |
Testicular Feminization
|
0.020 |
Biomarker
|
disease |
BEFREE |
Furthermore, high levels of IGF-binding protein-5 mRNA were detected in all genital skin fibroblast strains, whereby the 28-kDa band in the ligand blot, probably representing IGF-binding protein-5, was more abundant in complete androgen insensitivity genital skin fibroblasts.
|
11600534 |
2001 |
Crohn Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Here we studied IGF-I and IGFBP-5 in Crohn's disease tissue.
|
11292612 |
2001 |
Precancerous Conditions
|
0.010 |
Biomarker
|
group |
BEFREE |
These results suggest that the loss of IGFBP-5 and possibly IGF-R2, both of which can sequester IGF-I from IGF-R1, permits unhindered proliferation of the premalignant EVT in an IGF-I rich environment of the fetal-maternal interface.
|
11745462 |
2001 |
Endotoxemia
|
0.200 |
Biomarker
|
phenotype |
RGD |
Regulation of the acid-labile subunit in sustained endotoxemia.
|
12217886 |
2002 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, IGFBP-5 appears to play a decisive role in the control of proliferation of specific tumour cell types.
|
11874691 |
2002 |
Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of mitogenic doses of AlF(4)(-) and NaF on the mRNA levels and the protein level (in conditioned media [CM]) of several components of the IGF system (i.e., IGF-2, IGF binding protein [IGFBP]-4, and IGFBP-5) in human TE85 osteosarcoma cells.
|
11996908 |
2002 |
Osteosarcoma of bone
|
0.050 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of mitogenic doses of AlF(4)(-) and NaF on the mRNA levels and the protein level (in conditioned media [CM]) of several components of the IGF system (i.e., IGF-2, IGF binding protein [IGFBP]-4, and IGFBP-5) in human TE85 osteosarcoma cells.
|
11996908 |
2002 |
Childhood Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We evaluated the effect of mitogenic doses of AlF(4)(-) and NaF on the mRNA levels and the protein level (in conditioned media [CM]) of several components of the IGF system (i.e., IGF-2, IGF binding protein [IGFBP]-4, and IGFBP-5) in human TE85 osteosarcoma cells.
|
11996908 |
2002 |
Rheumatoid Arthritis
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Previous evidence that non-MHC IDDM loci overlap RA susceptibility loci made IGFBP5 and its region an interesting candidate locus which was tested for linkage.
|
11960310 |
2002 |
Neuroblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms.
|
11973331 |
2002 |
Central neuroblastoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Expression of insulin-like growth factor-binding protein 5 in neuroblastoma cells is regulated at the transcriptional level by c-Myb and B-Myb via direct and indirect mechanisms.
|
11973331 |
2002 |